Bristol Myers Squibb stock: Camzyos data extend pediatric case

Bristol Myers Squibb presented new clinical evidence for Camzyos on Friday, November 6, at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions in Chicago. The company's Bristol Myers Squibb press release said the Phase 3 SCOUT-HCM trial maintained a consistent efficacy and safety profile through 56 weeks.

The trial evaluated Camzyos, or mavacamten, in patients aged 12 to under 18 with symptomatic obstructive hypertrophic cardiomyopathy. Forty-four patients were randomized, and 43 completed the double-blind placebo-controlled period before entering active treatment.

Longer follow-up supports pediatric use

Patients who received Camzyos throughout the study recorded a mean reduction from baseline of 48.1 mmHg in the Valsalva left ventricular outflow tract gradient after 56 weeks. Patients who switched from placebo to Camzyos showed a similar degree of improvement.

Bristol Myers Squibb said no patient experienced a left ventricular ejection fraction below 50% during the 56-week evaluation. The company also said no new safety signals emerged, while treatment-related treatment-emergent adverse events and serious events remained low in the reported treatment periods.

The U.S. Food and Drug Administration approved Camzyos in September 2026 for pediatric patients weighing at least 30 kilograms with symptomatic obstructive hypertrophic cardiomyopathy. The approval was based on positive 28-week SCOUT-HCM results, making the longer follow-up relevant to the product's developing pediatric profile.

Pipeline focus remains ahead

Additional Camzyos presentations at the American Heart Association Scientific Sessions are scheduled through Monday, November 9. They cover clinical and real-world evidence in adult patients, including long-term safety and effectiveness analyses.

Bristol Myers Squibb stock traded at 55.91 euros on Lang & Schwarz at 11:14 CET on Saturday, November 7. The real-time quote of Bristol Myers Squibb stock provides the current trading view.

For the broader U.S. market context, see current S&P 500 market reports.

Find more news and analyses on Bristol Myers Squibb stock.